FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biology and medicine. A drug is prepared for local application on a corneal surface. As targets, there are offered to be used carbonic anhydrase II, IV and XII, adrenergic receptors: beta 1 and 2, and alpha IA, IB and ID, acetylcholinesterase, cyclooxygenases 1 and 2, ATP-ases: alpha-1, alpha-2, alpha-3, beta-1, beta-2, an endothelial leukocyte adhesion molecule (ELAM-1), angiotensin I conveting enzymes (ACE I and ACE II), angiotensin I receptors (ATR1 and ATR2) and renin; cochline.
EFFECT: application of RNA interference technique in treating eye diseases, preferentially glaucoma and uveitis.
36 cl, 2 tbl, 2 ex, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MEDIATED PHKi INHIBITION OF Rho-KINASE FOR TREATING OPHTHALMIC DISORDERS | 2006 |
|
RU2432165C2 |
| TREATMENT OF CNS DISORDERS | 2007 |
|
RU2426544C2 |
| TREATMENT OF INTESTINAL DISEASES | 2006 |
|
RU2418594C2 |
| iRNA-MEDIATED INHIBITION OF TUMOUR NECROSIS FACTOR-( RELATED CONDITIONS | 2007 |
|
RU2469090C2 |
| 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 EXPRESSION MODULATION FOR TREATING EYE DISEASES | 2006 |
|
RU2420582C2 |
| TREATING SIRTIUN 1 (SIRT1)-RELATED DISEASES BY INHIBITON OF NATURAL ANTISENSE TRANSCRIPT | 2009 |
|
RU2551234C2 |
| NEW MINIMUM UTR SEQUENCES | 2017 |
|
RU2759737C2 |
| KIRNA AND THEIR USE IN THE METHODS AND COMPOSITIONS FOR TREATMENT AND/OR PREVENTION OF EYE DISEASES | 2012 |
|
RU2653766C2 |
| TREATMENT OF DISEASES ASSOCIATED WITH ERYTHROPOIETIN (EPO) BY NATURAL EPO ANTISENSE TRANSCRIPT INHIBITION | 2009 |
|
RU2620970C2 |
| METHODS FOR GENETIC CONTROL INSECT INFESTATION IN PLANTS AND COMPOSITIONS USED THEREFOR | 2006 |
|
RU2478710C2 |
